Innova Captab starts Q1FY27 with margin 7.14 points below peers
The company said its Jammu facility is ramping up, while inventory linked to the plant affected net working capital.
Filed 11 Aug 2026, 18:32 IST · after market close · Innova Captab Ltd (INNOVACAP)
Key takeaways
- Other income was only Rs 2.01 cr against Rs 58.98 cr of pre-tax profit, making Q1FY27 earnings primarily operating-led.
- Innova Captab's 15.53% consolidated operating margin was 7.14 percentage points below the 22.67% median for 61 reported healthcare peers.
- Management said the four-block Jammu facility is seeing a steady ramp-up through existing customers and new client additions.
Price around the results
Operating-led earnings in Q1FY27
The consolidated quarter was primarily driven by operations rather than non-operating income: other income was Rs 2.01 cr against pre-tax profit of Rs 58.98 cr. After Rs 4.43 cr of interest and Rs 11.71 cr of depreciation, net profit stood at Rs 44.13 cr and EPS at Rs 7.71. The reported tax rate was 25.19%.
Operating margin trails the healthcare peer set
The 15.53% operating margin was below the 22.67% median among 61 healthcare companies that had reported the same quarter. The 7.14-percentage-point gap places Innova Captab 11th from the bottom of that peer comparison. With no sequential or year-on-year driver data provided, the margin gap is more informative here than a trend call.
Jammu expansion is moving into ramp-up
Management said the greenfield multipurpose facility in Kathua, Jammu, commercialised in Jan'25, has four independent blocks covering cephalosporin, penem, oral-solid, and large- and small-dosage categories. The company said the facility is seeing a steady ramp-up, supported by higher business from existing customers and the onboarding of new clients. Management also said inventory related to the Jammu plant affected net working capital. It said its focus remains on operational excellence, manufacturing efficiency and quality, and that it expects to sustain growth while enhancing profitability.
Results were filed after market close
The consolidated results were filed after market close on 11 Aug 2026. The filing was timestamped 18:32 IST.
Q1FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹471 cr |
| Other income | ₹2 cr |
| Expenses | ₹398 cr |
| Operating profit | ₹73 cr |
| Operating margin (%) | 15.53% |
| Interest | ₹4 cr |
| Depreciation | ₹12 cr |
| Profit before tax | ₹59 cr |
| Tax | ₹15 cr |
| Net profit | ₹44 cr |
| EPS (₹) | ₹7.71 |
Operating margin of 15.53% compares with a Healthcare sector median of 22.67% across 61 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The Jammu facility saw a steady ramp-up supported by existing customers and onboarding of new clients.
Guidance & outlook
- The company expects to sustain growth, enhance profitability and deliver long-term stakeholder value.
Expansion
- The Jammu expansion comprises a new greenfield multipurpose facility with four manufacturing blocks.
- The Jammu facility has four independent blocks covering multiple dosage and product categories.
New initiatives
- The company is focusing on operational excellence, manufacturing efficiency and quality to meet evolving market requirements.
Problems & risks
- Net working capital was impacted by increased inventory related to the Jammu plant.
What to watch
- Whether operating margin moves up from 15.53% and narrows the 7.14-percentage-point gap with the healthcare peer median.
- Whether the four-block Jammu facility's ramp-up is reflected in operating profit of Rs 73.12 cr.
- Whether the reported tax rate remains near 25.19%.